How to achieve a functional cure for chronic hepatitis B

More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with nucleos(t)ide analogues (NUC), lasting immune control is almost never seen. According to the current state of knowledge, those affected therefore require lifelong therapy. In the world’s first randomized controlled multicenter study – led by Leipzig University’s Faculty of Medicine and in partnership with the Centre for Clinical Studies (ZKS) – researchers have shown that many HBeAg-negative patients can achieve permanent immune control of hepatitis B if they discontinue antiviral therapy after a certain period of time. Their findingsopens in new tab/window are published in the high-impact journal, the Journal of Hepatologyopens in new tab/window.

Hepatitis B is an inflammation of the liver caused by the hepatitis B virus that can lead to serious problems such as liver cirrhosis or liver cancer and is easily transmitted through body fluids. An estimated 350 million are chronically infected, making chronic hepatitis B one of the most common viral infections worldwide. People with chronic hepatitis B usually have to take antiviral medication for their entire life in order to reduce the viral load and normalize inflammation levels in the liver. Antiviral therapy consists of the administration of nucleoside or nucleotide analogues, which in patients with the HBeAg-negative form almost never leads to the permanent immune control that would allow the termination of treatment. The antiviral therapy is associated with high costs for the healthcare system and can cause serious side effects.

Results currently published in the Journal of Hepatology show in a study of 166 HBeAg-negative patients from 20 clinics across Germany that after 96 weeks of observation many patients who discontinued an effective antiviral treatment that they had taken for at least four years achieved immune control of the disease. In 10% of the patients, immune control was demonstrated through loss of previously detectable hepatitis B surface antigen (HBsAg) in the blood, an event which is considered a functional cure of hepatitis B.

By the end of the study, in about 41% of patients, hepatitis B virus levels in the blood were reduced to below the level of 2,000 units per millilitre, which according to international treatment guidelines means that there is no longer an indication for renewed antiviral therapy. Additionally, 77% of patients no longer had elevated liver inflammation levels. In contrast, no patient who continued antiviral treatment showed HBsAg loss.

Study leader Professor Florian van Bömmel, senior physician in the Department of Hepatology at Leipzig University Hospital said, “We were able to show that in some patients discontinuing long-term therapy with nucleoside or nucleotide analogues after at least four years is more effective than continuing it, and that many patients no longer require antiviral therapy at all after discontinuation. In particular, patients who show low HBsAg levels when they discontinue treatment have a high chance of functional cure.”

After discontinuation of treatment, all of the patients initially experienced a resurgence of hepatitis B virus replication and many also experienced transient renewed liver inflammation. Some patients with severe liver inflammation were then restarted on antiviral therapy to prevent liver damage. Patients with liver cirrhosis were not included in the study for safety reasons. No serious adverse events related to discontinuation of therapy occurred during the study. “However, in other studies, severe cases of hepatic inflammation were observed in a few cases after antiviral therapy was discontinued. Stopping NUC treatment should therefore only be carried out under the supervision of an experienced physician,” said the study leader.

Professor van Bömmel and Professor Thomas Berg, head of the Department of Hepatology at Leipzig University Hospital, are confident that the results of the STOP-NUC trial will have a major impact on the overall development of hepatitis B therapy: “We expect that in the future international guidelines for the treatment of hepatitis B will refer to this study. By the middle of this year, results from the extension of the study will be evaluated and will show whether the number of patients with immune control continues to increase in the long term after discontinuation of antiviral treatment.”

---

Notes for editors

The article is “A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B,” by Florian van Bömmel, Kerstin Stein, Renate Heyne, Jörg Petersen, Peter Buggisch, Christoph Berg, Stefan Zeuzem, Andreas Stallmach, Martin Sprinzl, Eckart Schott, Anita Pathil-Warth, Ulrike von Arnim, Verena Keitel, Jürgen Lohmeyer, Karl-Georg Simon, Christian Trautwein, Andreas Trein, Dietrich Hüppe, Markus Cornberg, Frank Lammert, Patrick Ingiliz, Reinhart Zachoval, Holger Hinrichsen, Alexander Zipprich, Hartmuth Klinker, Julian Schulze zur Wiesch, Anett Schmiedeknecht, Oana Brosteanu, and Thomas Berg (https://doi.org/10.1016/j.jhep.2022.12.018opens in new tab/window). It appears online in the Journal of Hepatology, published by Elsevier.

The article is openly available at https://www.journal-of-hepatology.eu/article/S0168-8278(22)03470-5/fulltextopens in new tab/window.

The STOP-NUC trialopens in new tab/window was funded by the German Federal Ministry of Education and Research (BMBF) (funding code: 01KG1308).

Journalists wishing to interview the authors should contact Professor Florian van Bömmel, Department of Hepatology, Leipzig University Hospital, at +49 341 97-12330 or [email protected]opens in new tab/window.

About the Journal of Hepatology

The Journal of Hepatologyopens in new tab/window, the premier journal devoted to liver diseases, is the official journal of the European Association for the Study of the Liver (EASL). It publishes original papers, reviews, case reports, and letters to the Editor concerned with clinical and basic research in the field of hepatology. The journal has a 2021 Impact Factor of 30.083 (Source: Journal Citation Reports™ from Clarivate, 2022). www.journal-of-hepatology.euopens in new tab/window

About EASL

In the fifty plus years since EASLopens in new tab/window was founded, it has grown from a small organization that played host to 70 participants at its first meeting, to becoming the leading international liver association. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. www.easl.euopens in new tab/window

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundationopens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELXopens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.